Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints

Background People living with human immunodeficiency virus (PLHIV) have a 25-35–fold higher chance of being diagnosed with squamous-cell carcinoma of the anal canal (SCAC). Patients and methods We prospectively evaluated the safety and efficacy of retifanlimab in PLHIV and SCAC enrolled in the POD1UM-202 and POD1UM-303/InterAACT-2 studies; PLHIV with CD4+ cell count ≥200/μl and undetectable viral load were enrolled and continued on highly active antiretroviral therapy (HAART). HIV viral load and CD4+ cell counts were assessed every 8 weeks and could be reduced to every 6 months during safety and disease follow-up. Results Among the 20 patients with HIV enrolled, median age was 58 years, 70% were male, and 80% white. Nine patients received retifanlimab monotherapy and six patients received retifanlimab + platinum-based chemotherapy; five patients received placebo + chemotherapy. No consistent overall trend in CD4+ cell counts or loss of HIV control was observed; no treatment-emergent opportunistic infections were recorded. Immune-related adverse events were consistent among patients without HIV. Efficacy was broadly consistent across the overall study populations. Patient-reported outcomes showed no negative impact. Retifanlimab pharmacokinetics were independent of HIV status and not impacted by HAART. Conclusions This prospective evaluation, the first in PLHIV and SCAC, demonstrates that the efficacy of retifanlimab is qualitatively consistent with that in HIV-negative patients with no excess toxicity or reduced HIV control, supporting the inclusion of HIV-positive patients in immunotherapy trials.

Authors

Institutions

Publication Details

Journal
ESMO Gastrointestinal Oncology
Published
2026-11-18
DOI
https://doi.org/10.1016/j.esmogo.2026.100441
Primary Topic
Colorectal and Anal Carcinomas
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints

Pauline Rochefort, Jean‐Philippe Spano, L. Evesque, M. Guillot Morales et al.
6 links
ESMO Gastrointestinal Oncology
Colorectal and Anal Carcinomas
article

Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints

Pauline Rochefort, Jean‐Philippe Spano, L. Evesque, M. Guillot Morales, M. C. Munteanu, Sara Lonardi, Anderley Gordon, Federica Morano, Duncan Charles Gilbert, Frank Van Fraeyenhove, Michel Pierre Ducreux, Edward Jae-Hoon Kim, A. Vozy, X. Xu, M. Jones, J. Capdevila
article en

Abstract

Background People living with human immunodeficiency virus (PLHIV) have a 25-35–fold higher chance of being diagnosed with squamous-cell carcinoma of the anal canal (SCAC). Patients and methods We prospectively evaluated the safety and efficacy of retifanlimab in PLHIV and SCAC enrolled in the POD1UM-202 and POD1UM-303/InterAACT-2 studies; PLHIV with CD4+ cell count ≥200/μl and undetectable viral load were enrolled and continued on highly active antiretroviral therapy (HAART). HIV viral load and CD4+ cell counts were assessed every 8 weeks and could be reduced to every 6 months during safety and disease follow-up. Results Among the 20 patients with HIV enrolled, median age was 58 years, 70% were male, and 80% white. Nine patients received retifanlimab monotherapy and six patients received retifanlimab + platinum-based chemotherapy; five patients received placebo + chemotherapy. No consistent overall trend in CD4+ cell counts or loss of HIV control was observed; no treatment-emergent opportunistic infections were recorded. Immune-related adverse events were consistent among patients without HIV. Efficacy was broadly consistent across the overall study populations. Patient-reported outcomes showed no negative impact. Retifanlimab pharmacokinetics were independent of HIV status and not impacted by HAART. Conclusions This prospective evaluation, the first in PLHIV and SCAC, demonstrates that the efficacy of retifanlimab is qualitatively consistent with that in HIV-negative patients with no excess toxicity or reduced HIV control, supporting the inclusion of HIV-positive patients in immunotherapy trials.

ESMO Gastrointestinal OncologyVol. 14
Royal Marsden NHS Foundation Trust (GB), Inserm (FR), Institut Gustave Roussy (FR), Sorbonne Université (FR), Assistance Publique – Hôpitaux de Paris (FR), Centre Léon Bérard (FR), Istituto Oncologico Veneto (IT), ZNA Middelheim Hospital (BE), Royal Marsden Hospital (GB), Pitié-Salpêtrière Hospital (FR), Vall d'Hebron Hospital Universitari (ES), Ziekenhuisnetwerk Antwerpen Stuivenberg (BE), Centre Antoine Lacassagne (FR), Hospital Universitario Son Espases (ES), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Vall d'Hebron Institute of Oncology (ES), UC Davis Comprehensive Cancer Center (US), University College London (GB), Incyte (United States) (US)
Incyte
Good health and well-being
Colorectal and Anal Carcinomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon